Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
Clinical trial NCT04563871 · COMPLETED
Trial details
- NCT number
- NCT04563871
- Sponsor
- Sehhoon Park
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-17
- Primary completion
- 2023-10-25
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.